Market Report Source

Overview

Medicines in the cancer therapeutic area account for the third largest source of revenue within the pharma industry. The cancer market has experienced significant innovative change in recent years, creating attractive opportunities for a range of new and established biotechnology players as well as established pharma companies. Although new product development continues to involve substantial levels of risk, innovation is the key driving force in the market, and has led to the competitive exclusion of several of the industry’s traditional competitors. With successful launches now being applied to multiple indications faster than ever before, subsequent increases in product sales volumes are rapidly changing the competitive landscape of the cancer market.

The Cancer Market Outlook to 2012 is a new report published by Business Insights that provides comprehensive coverage of the major markets in the global cancer area, incorporating a detailed epidemiological analysis of the nine major indications and key factors impacting their prevalence. Current leading brands of treatment within each cancer indication are analysed and eight of the market’s leading players are profiled. With coverage of over 9% of the total market for cancer products, this report profiles the factors and underlying trends that are driving market transformation and identifies the most promising areas of potential growth. Forecasts for currently marketed and key pipeline products over the 2 6-12 period are also provided. Discover the key market trends and growth drivers of the cancer market, assess the competitive dynamics of leading pharma companies and evaluate the future prospects of major products with this new report.

Some key findings from this report:

• The cancer market expanded by 17.9% during 2006 and is forecast to reach $40.9b by 2012. The highest growth will occur in the antineoplastic class of drugs, which is expected to become the primary growth driver of the cancer market over the next four years.
• New launches such as Tykerb, Sutent and Nexavar will continue to drive rapid market growth due to their utility across multiple indications and specific side-effects profiles.
• The leading eight companies represented $17,927m (65.3%) of the of the global cancer market in 2006. AstraZeneca and Novartis are forecast to acheive the most rapid growth in their cancer portfolios over the forecast period, with modest gains expected for Amgen, Sanofi-Aventis and Lilly. Schering-Plough is forecast to register the weakest performance of any major player.
• Major companies have begun to focus R&D activities upon the development of compounds with strong prospects across multiple indications, as efforts to create blockbuster products intensify. Future blockbusters are forecast to include AstraZeneca’s Zactima and Recentin as well as a Merck’s cervical cancer vaccine, Gardasil.

Top five reasons to order your copy today:

• Assess patient potential, treatment trends and sales patterns across major cancer indications with this report’s detailed analysis of markets including Japan, France, Germany, Italy, Spain, the UK and the US.
• Measure the market performance and strategic positioning of major pharmaceutical corporations with this report’s evaluation of the franchises and market shares of Roche, Amgen, Sanofi-Aventis, AstraZeneca, Novartis, Pfizer, Schering-Plough and Lilly.
• Discover the market dynamics of the cancer area and understand the impact of recent key events by assessing major market trends, growth drivers and the latest issues affecting product development.
• Compare the future prospects of key players and forecast sales of leading products across major indications to 2012 with this report’s analysis of sales focus by drug class, currently marketed portfolios, R&D pipelines, and trends in promotional spend for key brands.
• Identify the strategies that offer the greatest success potential within the future cancer market and understand the challenges currently facing companies within this therapeutic area.

Key issues examined in this report:

• Vaccine approval. The approval of Merck’s cervical cancer vaccine Gardasil in June 2006 marked a major milestone in cancer prevention. However GSK’s rival vaccine, approved in the EU in September 2007, is forecast to instigate competition for market domination.
• The generic impact. With several leading blockbuster oncology products set to lose patent protection over the forecast period, immense opportunities will emerge for generic manufacturers.
• Product uptake. Cost containment policies across the major markets have limited the uptake of numerous leading cancer therapies. Lilly’s Alimta has market approval in the EU and US, but a higher price point has limited product uptake in some European markets. Genentech/Roche’s Avastin and OSI/Roche/Genentech’s Tarceva have experienced similar difficulties in product uptake.
• Key Indications. Colorectal cancer, NSCLC, breast and ovarian cancer are the most common indications targeted by drugs in development. Additional indications such as renal cell carcinoma and NHL offer significant incentives if molecules are granted orphan drug status.

Your questions answered:

• Which indications will experience the greatest growth in the global cancer market over the period 2007-12?
• How have recent major product launches performed?
• What is the forecast market potential of the most exciting compounds currently in development for cancer indications?
• Which companies are best positioned for future success?
• What is the forecast market size and growth rate over the period 2007-2012 across the major cancer indications?
• How will generic competition influence the future of branded products and which defensive strategies provide the most effective protection?
• Which pipeline products offer the highest growth potential?
• What will be the competitive landscape of leukaemia, lymphoma, lung, breast, pancreatic, colorectal, and prostate cancer in 2012?

Table of Contents

Executive Summary
Patient potential
Global market analysis
Pipeline analysis
Competitive landscape

Chapter 1 Epidemiology of cancer
Summary
Introduction
Overview
Lung cancer Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Colorectal cancer
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Breast cancer
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Ovarian cancer
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Uterine and cervical cancer
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Leukemia
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Prostate cancer
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Pancreatic cancer
Overview
Diagnosis, treatment and management
Epidemiology
Forecast prevalence
Lymphomas Overview
Diagnosis, treatment and management
Epidemiology
Forecast prevalence

Chapter 2 Global market analysis
Summary
Introduction
Market analysis by country
Trends in generics usage and licensing
Market analysis by drug class
Leading brands dynamics
Key events in the cancer market
Antineoplastics
Competitive dynamics of antineoplastics
Leading brands of antineoplastics
Antineoplastic MAb market analysis
Market dynamics
Key brands analysis
Vinka alkaloid market analysis
Market dynamics
Key brands analysis
Anti-metabolites
Market dynamics
Key brands analysis
Other antineoplastics
Market dynamics
Antineoplastic sales forecasts to 2012
Immunostimulants
Competitive dynamics of immunostimulants
Leading brands of immunostimulants
Interferon market analysis
Market dynamics
Key brands analysis
Other immunostimulants
Market dynamics
Key brand analysis
Immunostimulant sales forecasts to 2012
Cytostatic hormonal therapies
Competitive dynamics of cytostatic hormonal therapies
Leading brands of cytostatic hormonal therapies
LHRH agonists market analysis
Market dynamics
Key brands analysis
Aromatase inhibitors
Market dynamics
Key brands analysis
Anti-estrogens
Market dynamics
Key brand analysis
Anti-androgens
Cytostatic hormonal therapy sales forecasts to 2012
Total cancer market sales forecasts to 2012

Chapter 3 Pipeline Analysis
Summary
Introduction
Key trends in R&D
Need for drugs with improved tumor selectivity
Increased focus on cancer vaccine pipeline
Cost containment policies emerging as barrier for drug development
The cancer pipeline
Leading drugs in development
Profiles of key pipeline products
Phase III compounds
Enzastaurin
BiovaxID
HuMax-CD20 (ofatumumab)
Recentin (cediranib)
Zactima (vandetanib)
Recently approved/marketed drugs
Tasigna (nilotinib)
Gardasil and Cervarix
Vectibix (panitumumab)
Nexavar (sorafenib)
Sutent (sunitinib)
Tykerb (lapatinib)
Pipeline forecasts
Factors affecting forecasts
Cancer therapeutic area forecasts

Chapter 4 Competitive Landscape
Summary
Introduction
Company market shares
Roche
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Amgen
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Sanofi-Aventis
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
AstraZeneca
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Novartis
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Pfizer
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Schering-Plough
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Eli Lilly
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth

Chapter 5 Appendix
IMS data
Antineoplastic and immunomodulating agents
L1: Cytostatics
L2: Cytostatic hormone therapy
L3: Immunostimulating agents
Licensing status as per IMS Health
Original brand
Other brand
Licensed brand
Not-coded product
Unbranded/ generic product

Index

List of Figures
Figure 1.1: Overview of cancer etiology
Figure 2.2: Worldwide cancer market share by geography, 2006
Figure 2.3: Sales of cancer brands by license type, 2005-06
Figure 2.4: Competitive dynamics of the global cancer market by drug class, 2006
Figure 2.5: Competitive dynamics of the leading brands in the global cancer market, 2005-06
Figure 2.6: Competitive dynamics of the major antineoplastic classes in the global cancer market, 2005–06
Figure 2.7: Competitive dynamics of leading brands in the antineoplastic market, 2005-06
Figure 2.8: Competitive dynamics of the major immunostimulant classes in the global cancer market, 2005–06
Figure 2.9: Competitive dynamics of the leading brands in the global cancer immunostimulant market, 2005-06
Figure 2.10: Competitive dynamics of the major cytostatic hormonal therapy classes in the global cancer market, 2005–06
Figure 2.11: Competitive dynamics of the leading brands in the global cytostatic hormonal therapy market, 2005-06
Figure 3.12: Driver and resistors in cancer R&D, 2007
Figure 3.13: Oncology pipeline by indication and stage of development, 2006
Figure 3.14: Recently launched products and late-stage R&D compounds indicated for the treatment of cancer, 2006
Figure 4.15: Competitive dynamics of the leading players in the global cancer market, 2006
Figure 4.16: Roche’s cancer sales by drug class, 2006
Figure 4.17: Amgen’s cancer sales by drug class, 2006
Figure 4.18: Sanofi-Aventis’ cancer sales by drug class, 2006
Figure 4.19: AstraZeneca’s cancer sales by drug class, 2006
Figure 4.20: Novartis’ cancer sales by drug class, 2006
Figure 4.21: Pfizer’s cancer sales by drug class, 2006
Figure 4.22: Schering-Plough’s cancer sales by drug class, 2006
Figure 4.23: Lilly’s cancer sales by drug class, 2006

List of Tables
Table 1.1: Estimated prevalence of lung cancer across the seven major markets, 2006
Table 1.2: Forecast epidemiology of lung cancer across the seven major markets, 2006-12
Table 1.3: Estimated epidemiology of colorectal cancer across the seven major markets, 2006
Table 1.4: Forecast epidemiology of colorectal cancer across the seven major markets, 2006-12
Table 1.5: Estimated epidemiology of breast cancer across the seven major markets, 2006
Table 1.6: Forecast epidemiology of breast cancer across the seven major markets, 2006-12
Table 1.7: Estimated epidemiology of ovarian cancer across the seven major markets, 2006
Table 1.8: Forecast epidemiology of ovarian cancer across the seven major markets, 2006-12
Table 1.9: Estimated epidemiology of uterine cancer across the seven major markets, 2006
Table 1.10: Forecast epidemiology of uterine cancer across the seven major markets, 2006-12
Table 1.11: Estimated epidemiology of leukemia across the seven major markets, 2006 47
Table 1.12: Forecast epidemiology of leukemia across the seven major markets, 2006-12 49
Table 1.13: Estimated epidemiology of prostate cancer across the seven major markets, 2006 52
Table 1.14: Forecast epidemiology of prostate cancer across the seven major markets, 2006-12 54
Table 1.15: Estimated epidemiology of pancreatic cancer across the seven major markets, 2006 56
Table 1.16: Forecast epidemiology of pancreatic cancer across the seven major markets, 2006-12
Table 1.17: Estimated epidemiology of lymphomas across the seven major markets, 2006
Table 1.18: Forecast epidemiology of lymphomas across the seven major markets, 2006-12
Table 2.19: Breakdown of the global cancer market by drug class, 2003-06
Table 2.20: Leading products in the global cancer market, 2005–06
Table 2.21: Breakdown of the global antineoplastic market by drug class
Table 2.22: Leading therapies in the global antineoplastics market, 2005–06
Table 2.23: Antineoplastic sales forecast, 2006-12
Table 2.24: Breakdown of the global immunostimulant market by drug class, 2003-06
Table 2.25: Leading therapies in the global immunostimulant market, 2005–06
Table 2.26: Immunostimulant sales forecast, 2006-12
Table 2.27: Global cytostatic hormonal therapy market by drug class, 2003-06
Table 2.28: Leading therapies in the global cytostatic hormonal therapy market, 2005–06
Table 2.29: Cytostatic hormonal therapy sales forecast, 2006-12
Table 2.30: Cancer sales forecasts by drug class, 2006-112
Table 3.31: Cancer pipeline sales forecasts, 2006-12
Table 4.32: Leading players in the cancer market, 2005-06
Table 4.33: Roche’s cancer product portfolio, 2005-06
Table 4.34: Roche’s cancer R&D product pipeline, 2007
Table 4.35: Amgen’s cancer product portfolio, 2005-06
Table 4.36: Amgen’s cancer R&D product pipeline, 2007
Table 4.37: Sanofi-Aventis’ cancer product portfolio, 2005-06
Table 4.38: Sanofi-Aventis’ cancer R&D product pipeline, 2007
Table 4.39: AstraZeneca’s cancer product portfolio, 2005-06
Table 4.40: AstraZeneca’s cancer R&D product pipeline, 2007
Table 4.41: Novartis’ cancer product portfolio, 2005-06
Table 4.42: Novartis’ cancer R&D product pipeline, 2007
Table 4.43: Pfizer’s cancer product portfolio, 2005-06
Table 4.44: Pfizer’s cancer R&D product pipeline, 2007
Table 4.45: Schering-Plough’s cancer product portfolio, 2005-06
Table 4.46: Schering-Plough’s cancer R&D product pipeline, 2007
Table 4.47: Lilly’s cancer product portfolio, 2005-06
Table 4.48: Lilly’s cancer R&D product pipeline, 2007